Form 4: ACADIA CFO Schneyer Reports Routine Stock Transactions

Acadia Pharmaceuticals' EVP and CFO, Mark C. Schneyer, reported the acquisition of common stock through RSU vesting and an employee stock purchase plan, alongside a sale to cover tax obligations.

Summary

• Mark C. Schneyer, Executive Vice President and Chief Financial Officer of ACADIA PHARMACEUTICALS INC. (ACAD), reported transactions involving the company's common stock.
• On November 17, 2025, Mr. Schneyer acquired 9,913 shares of common stock through the vesting of restricted stock units (RSUs).
• On the same date, November 17, 2025, an additional 9,913 shares of common stock were acquired through the vesting of other restricted stock units.
• These transactions followed the acquisition of 327 shares of common stock on November 14, 2025, pursuant to an employee stock purchase plan.
• On November 18, 2025, Mr. Schneyer disposed of 10,262 shares of common stock at a weighted average price of $23.6907 per share.
• The sale was mandatory and made to cover withholding taxes and tax-related items imposed by the Issuer in connection with the vesting of restricted stock units, consistent with a Rule 10b5-1(c) plan.
• Following these reported transactions, Mr. Schneyer beneficially owns 53,338 shares of ACADIA PHARMACEUTICALS INC. common stock.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (RSU vesting, ESPP acquisition, and tax-related sales) which are common for executives and do not inherently signal significant positive or negative news about the company's operational or financial performance.

Positives

• The vesting of restricted stock units indicates the fulfillment of long-term incentive compensation for the EVP, CFO, aligning management interests with shareholder value.
• The acquisition of shares through an employee stock purchase plan demonstrates continued personal investment by the executive in the company's equity.

Negatives

• The sale of 10,262 shares, although for tax purposes, reduces the direct beneficial ownership of the EVP, CFO.

Future Outlook

The filing details the vesting schedule for restricted stock units, indicating future vesting events. Specifically, 37.5% of certain RSUs vest 18 months from the grant date, 12.5% on the second anniversary, and 25% on each of the third and fourth anniversaries. Some RSUs may also vest earlier if the Issuer's common stock achieves a specified price per share over a specified trading period.

Industry Context

This filing is a routine disclosure of insider transactions, common across all publicly traded industries, and does not provide specific insights into broader industry trends or competitive landscape for the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders may note the continued equity participation of a key executive (CFO) through RSU vesting and ESPP, indicating alignment of interests.
• The tax-related sale is a common practice and generally does not reflect a change in the executive's confidence in the company.

Key Dates

Recommendation

The filing details routine insider transactions, specifically the vesting of restricted stock units and subsequent sales to cover tax obligations. These are common occurrences for executives and do not inherently signal a change in the company's fundamental outlook or performance. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter an investment thesis.

Keywords

ACADIA PHARMACEUTICALS, ACAD, Form 4, Insider Transaction, Mark C. Schneyer, CFO, Restricted Stock Units, RSU Vesting, Employee Stock Purchase Plan, Stock Sale, Tax Withholding